about
The Global HIV/AIDS Vaccine Enterprise: scientific strategic planCo-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cellsHuman Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B EnvelopeExpression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol and gagpol DNA vaccinesSensitivity analyses comparing time-to-event outcomes only existing in a subset selected postrandomization and relaxing monotonicityNew recombinant vaccines based on the use of prokaryotic antigen-display systems.On modeling HIV and T cells in vivo: assessing causal estimators in vaccine trials.Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variablesElimination of helminth infection restores HIV-1C vaccine-specific T cell responses independent of helminth-induced IL-10HIV neutralizing antibodies: clinical correlates and implications for vaccines.Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys.Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1Immunogen sequence: the fourth tier of AIDS vaccine design.Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremiaConditional live virus as a novel approach towards a safe live attenuated HIV vaccine.ALVAC-HIV vaccines: clinical trial experience focusing on progress in vaccine development.The Trojan exosome hypothesisT cell cross-reactivity and conformational changes during TCR engagement.Conservation of HIV-1 T cell epitopes across time and clades: validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccineMultigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challengeSafety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects.Identification of immunogenic HLA-B7 "Achilles' heel" epitopes within highly conserved regions of HIVFrequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies.Sensitivity Analyses Comparing Time-to-Event Outcomes Existing Only in a Subset Selected PostrandomizationA simple one-step method for the preparation of HIV-1 envelope glycoprotein immunogens based on a CD4 mimic peptide.Viral sequence diversity: challenges for AIDS vaccine designs.Enhanced antibody responses to an HIV-1 membrane-proximal external region antigen in mice reconstituted with cultured lymphocytes.Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques.PROPORTIONAL HAZARDS MODELS WITH CONTINUOUS MARKS.Highly efficient neutralization by plasma antibodies from human immunodeficiency virus type-1 infected individuals on antiretroviral drug therapy.A comparison of eight methods for the dual-endpoint evaluation of efficacy in a proof-of-concept HIV vaccine trial.Further progress on defining highly conserved immunogenic epitopes for a global HIV vaccine: HLA-A3-restricted GAIA vaccine epitopes
P2860
Q21563445-71D57E42-355A-4BF3-9D49-A25B34961A2BQ28732043-0A64D95E-5EAC-4D63-92AA-6FF79657E58BQ29307502-682A1988-C6E7-429E-B646-90D1D4041C2CQ30332833-A06710CE-608A-466A-B565-F8F11B79FE8FQ30501153-D90B9AC0-76DC-4395-A206-13A2F38B78A9Q33210092-EE4E1416-7FDB-40F6-80DF-D781DFABF4C7Q33247446-710F4B9F-909D-4608-A7C0-602625E3F6C9Q33614495-B8F1EFA0-5824-412F-A6E4-E2E1DF1D60A5Q33699560-D14F00A9-5053-4556-8A61-F5C17C2D3E0DQ33703451-16C52A30-ED0A-4914-9572-710E611C4B1EQ33834916-F53AB85E-0E4F-44ED-8A7A-10BA2D449812Q33883887-90E05415-A841-4958-921D-47B860859C11Q34337482-41EABA0B-EA2D-46B4-B188-737F4EFAA9C5Q34999724-0515FA32-B85E-41F4-9283-8EC0A5001348Q35077039-E2F92101-F2B6-4445-9371-36870773176AQ35193454-3F297A57-3C9A-4880-BDF3-4821F1BBFF8CQ35851797-C45AD248-6710-4F93-A998-0C45B89CE9FBQ35976953-64E68988-4FEA-4A0E-BFBC-66D7F1FCEC7EQ36399643-B9E7B84D-9045-43DC-9E39-C4FBA906FAD2Q36467153-B184ADE5-976B-409E-B9C2-3561516E61D4Q36538907-A518030E-18B5-413B-9C6A-D290C6FF299AQ36628032-C9BBA7D1-72F8-4ABA-85FC-AE346DF856DEQ36910003-54065313-B1B6-469C-B2DA-F12A700328E7Q37033269-26AA2073-11E4-45CA-A83E-CE67F43B2D5AQ37035713-E00D249A-649A-463B-94D6-FEEE16E44CE1Q37102810-7EAE67E0-D231-4F28-93D7-3D9A3176FCAAQ37316023-D239B1D4-DBAB-4A2F-A082-D5444F5F6239Q37730206-311BDBA4-8994-4489-8EE3-87F9D85CB55AQ37743813-B333CB3B-3045-4599-9170-199AEEB0DCB6Q42041320-12D32C81-BA3C-4386-9EA0-BAD0A1E7E32AQ42228026-2E29E671-C3E8-4D4B-8E4C-46FBD0F84A38Q50475666-7B3918DF-CECC-458D-8461-75FE84ED18E4Q56999671-CE0A17F4-95A4-49D1-9B76-2B0C14F0E5BC
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Clinical trials of HIV vaccines.
@ast
Clinical trials of HIV vaccines.
@en
type
label
Clinical trials of HIV vaccines.
@ast
Clinical trials of HIV vaccines.
@en
prefLabel
Clinical trials of HIV vaccines.
@ast
Clinical trials of HIV vaccines.
@en
P1476
Clinical trials of HIV vaccines.
@en
P304
P356
10.1146/ANNUREV.MED.53.082901.104035
P577
2002-01-01T00:00:00Z